NCT05485259View on ClinicalTrials.gov

Effect of Alpha-lipoic Acid on Regression of Low-grade Squamous Intraepithelial Lesions (LSIL)

NACompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

January 15, 2020

Primary Completion Date

January 15, 2022

Study Completion Date

June 15, 2022

Conditions
Low-Grade Squamous Intraepithelial Lesions
Interventions
DIETARY_SUPPLEMENT

DL-alpha lipoic acid

Treatment group recieves 600 mg of DL-alpha lipoic acid daily, per os, for 3 months.

OTHER

placebo (rice starch)

Placebo group recieves 600 mg (2x300 mg) of placebo (rice starch) daily, per os, for 3 months

Trial Locations (2)

10000

University of Zagreb, Zagreb

Unknown

University Clinical Center Tuzla, Tuzla

All Listed Sponsors
collaborator

University Clinical Center Tuzla

OTHER

lead

University of Zagreb

OTHER

NCT05485259 - Effect of Alpha-lipoic Acid on Regression of Low-grade Squamous Intraepithelial Lesions (LSIL) | Biotech Hunter | Biotech Hunter